Kashima J, et al. - Researchers evaluated soluble CD27 (sCD27) levels in patients with advanced lung cancer. They also focused on the correlation of sCD27 levels with survival and clinicopathologic parameters in these patients. This study was performed on 96 patients, including 73 with adenocarcinoma, 7 with squamous cell carcinoma, and 15 with small cell carcinoma. The median serum sCD27 level was estimated to be 36.54 U/mL; this was lower when compared with that earlier recorded for patients with lung cancer, including those with localized stages. Higher sCD27 levels were exhibited by patients with squamous cell carcinoma. A significant correlation of age, performance status, and serum albumin levels, with serum sCD27 level, was evident. Poor prognosis was reported in correlation with the high sCD27 level. The immune-exhausted status of patients with advanced lung cancer may be reflected by the high sCD27 level.